-
公开(公告)号：US12173069B2
公开(公告)日：2024-12-24
申请号：US16982277
申请日：2019-03-19
Inventor： Robert J. Johnston , Arvind Rajpal , Paul O. Sheppard , Luis Borges , Andrew Rankin , Keith Sadoon Bahjat , Alan J. Korman , Xiaodi Deng , Lin Hui Su , Ginger Rakestraw , Jason R. Pinckney , David A. Critton , Guodong Chen , Richard Y. Huang , Ekaterina G. Deyanova
Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
-
公开(公告)号：US10653791B2
公开(公告)日：2020-05-19
申请号：US15520954
申请日：2015-11-19
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Nils Lonberg , Alan J. Korman , Mark J. Selby , Bryan C. Barnhart , Aaron P. Yamniuk , Mohan Srinivasan , Karla A. Henning , Michelle Minhua Han , Ming Lei , Liang Schweizer , Sandra V. Hatcher , Arvind Rajpal
IPC: C07K16/00 , C07K16/28 , C07K16/30 , A61K47/68 , A61K39/395
Abstract: Provided herein are heavy chain constant regions (referred to as “modified heavy chain constant regions”), or functionally equivalent fragments thereof, that enhance biological properties of antibodies relative to the same antibodies in unmodified form. An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge.
-
公开(公告)号：US20190055321A1
公开(公告)日：2019-02-21
申请号：US16103654
申请日：2018-08-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Stanley R. Krystek, JR. , Yong Zhang , Gregory D. Vite , Arvind Rajpal , Chetana Rao-Naik , Paul E. Morin , Mohan Srinivasan , Zheng Lin , Virginie Lafont , Alla Pritsker
IPC: C07K16/46
Abstract: A prodrugged antibody has a blocking moiety attached to a Cys on its heavy or light chain via a linker having a cleavable moiety. The blocking moiety inhibits binding of the antibody to its antigen. Cleavage of the cleavable moiety releases the blocking moiety and restores ability of the antibody to bind to its antigen.
-
公开(公告)号：US12091462B2
公开(公告)日：2024-09-17
申请号：US17258866
申请日：2019-07-10
Inventor： Robert J. Johnston , Arvind Rajpal , Paul O. Sheppard , Luis Borges , Andrew Rankin , Keith Sadoon Bahjat , Alan J. Korman , Xiaodi Deng , Lin Hui Su , Ginger Rakestraw , Jason R. Pinckney , David A. Critton , Guodong Chen , Richard Y. Huang , Ekaterina G. Deyanova , Michael Quigley , Hadia Lemar , Akbar Nayeem
CPC classification number: C07K16/2827 , A61P35/00 , A61K2039/507 , C07K2317/34 , C07K2317/74 , C07K2317/76 , C07K2317/92
Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
-
公开(公告)号：US20150203574A1
公开(公告)日：2015-07-23
申请号：US14473997
申请日：2014-08-29
Applicant: Pfizer Inc. , BRISTOL-MYERS SQUIBB COMPANY
Inventor： Arvind Rajpal , Madhav Narasimha Devalaraja , Kristopher Toy , Lan Yang , Haichun Huang , Jun Zhang , Peter Brams , Brigitte Devaux , David B. Passmore
IPC: C07K16/24
CPC classification number: C07K16/248 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/92
Abstract: Antibodies and antigen-binding portions thereof that bind to human IL-6 are provided. Also provided are nucleic acids encoding such antibodies and antigen binding portions, methods of making such antibodies and antigen binding portions, compositions comprising such antibodies or antigen binding portions, and uses of such antibodies or antigen binding portions.
-
Patent Agency Ranking
公开(公告)号：US11623965B2
公开(公告)日：2023-04-11
申请号：US16103654
申请日：2018-08-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Stanley R. Krystek, Jr. , Yong Zhang , Gregory D. Vite , Arvind Rajpal , Chetana Rao-Naik , Paul E. Morin , Mohan Srinivasan , Zheng Lin , Virginie Lafont , Alla Pritsker
Abstract: A prodrugged antibody has a blocking moiety attached to a Cys on its heavy or light chain via a linker having a cleavable moiety. The blocking moiety inhibits binding of the antibody to its antigen. Cleavage of the cleavable moiety releases the blocking moiety and restores ability of the antibody to bind to its antigen.
-
公开(公告)号：US11306150B2
公开(公告)日：2022-04-19
申请号：US16476814
申请日：2018-01-10
Inventor： Robert J. Johnston , Andrew Rankin , Arathi Krishnakumar , Paul O. Sheppard , Arvind Rajpal
Abstract: Methods of identifying and using PSGL-1 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer. PSGL-1 antagonists include, but are not limited to, antibodies that bind PSGL-1 and antibodies that bind VISTA, wherein the antibodies inhibit PSGL-1 binding to VISTA, e.g., at acidic pH (e.g., pH 6.0), as well as PSGL-1 and VISTA extracellular domain polypeptides.
-
公开(公告)号：US20190330364A1
公开(公告)日：2019-10-31
申请号：US16476814
申请日：2018-01-10
Inventor： Robert J. Johnston , Andrew Rankin , Arathi Krishnakumar , Paul O. Sheppard , Arvind Rajpal
IPC: C07K16/28
Abstract: Methods of identifying and using PSGL-1 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer. PSGL-1 antagonists include, but are not limited to, antibodies that bind PSGL-1 and antibodies that bind VISTA, wherein the antibodies inhibit PSGL-1 binding to VISTA, e.g., at acidic pH (e.g., pH 6.0), as well as PSGL-1 and VISTA extracellular domain polypeptides.
-
公开(公告)号：US09840562B2
公开(公告)日：2017-12-12
申请号：US14692948
申请日：2015-04-22
Applicant: Pfizer Inc. , Bristol-Myers Squibb Company
Inventor： Jing Min , Yanli Wu , Rory F. Finn , Barrett R. Thiele , Wei Liao , Ronald P. Gladue , Arvind Rajpal , Timothy J. Paradis , Peter Brams , Brigitte Devaux , Yi Wu , Kristopher Toy , Heidi N. LeBlanc , Haichun Huang
CPC classification number: C07K16/2878 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/565 , C07K2317/92
Abstract: The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.
-
公开(公告)号：US12195535B2
公开(公告)日：2025-01-14
申请号：US18162991
申请日：2023-02-01
Inventor： Robert J. Johnston , Arvind Rajpal , Paul O. Sheppard , Luis Borges , Andrew Rankin , Keith Sadoon Bahjat , Alan J. Korman , Andy X. Deng , Lin Hui Su , Ginger Rakestraw
IPC: C07K16/28
Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
-
-
-
-
-
-
-
-
-
Search Results
24
records
(took 0.019 seconds)
